213 related articles for article (PubMed ID: 35935966)
1. Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS1
Pantazica AM; Dobrica MO; Lazar C; Scurtu C; Tucureanu C; Caras I; Ionescu I; Costache A; Onu A; Clarke JL; Stavaru C; Branza-Nichita N
Front Immunol; 2022; 13():941243. PubMed ID: 35935966
[TBL] [Abstract][Full Text] [Related]
2. A novel chimeric Hepatitis B virus S/preS1 antigen produced in mammalian and plant cells elicits stronger humoral and cellular immune response than the standard vaccine-constituent, S protein.
Dobrica MO; Lazar C; Paruch L; Skomedal H; Steen H; Haugslien S; Tucureanu C; Caras I; Onu A; Ciulean S; Branzan A; Clarke JL; Stavaru C; Branza-Nichita N
Antiviral Res; 2017 Aug; 144():256-265. PubMed ID: 28666757
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of a chimeric Hepatitis B Virus S/preS1 antigen produced in lettuce triggers infection neutralizing antibodies in mice.
Dobrica MO; Lazar C; Paruch L; van Eerde A; Clarke JL; Tucureanu C; Caras I; Ciulean S; Onu A; Tofan V; Branzan A; Urban S; Stavaru C; Branza-Nichita N
Vaccine; 2018 Sep; 36(38):5789-5795. PubMed ID: 30082163
[TBL] [Abstract][Full Text] [Related]
4. The "humanized" N-glycosylation pathway in CRISPR/Cas9-edited Nicotiana benthamiana significantly enhances the immunogenicity of a S/preS1 Hepatitis B Virus antigen and the virus-neutralizing antibody response in vaccinated mice.
Pantazica AM; van Eerde A; Dobrica MO; Caras I; Ionescu I; Costache A; Tucureanu C; Steen H; Lazar C; Heldal I; Haugslien S; Onu A; Stavaru C; Branza-Nichita N; Liu Clarke J
Plant Biotechnol J; 2023 Jun; 21(6):1176-1190. PubMed ID: 36779605
[TBL] [Abstract][Full Text] [Related]
5. The immune response of rhesus macaques to novel vaccines comprising hepatitis B virus S, PreS1, and Core antigens.
Chuai X; Xie B; Chen H; Tan X; Wang W; Huang B; Deng Y; Li W; Tan W
Vaccine; 2018 Jun; 36(26):3740-3746. PubMed ID: 29778513
[TBL] [Abstract][Full Text] [Related]
6. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.
Bremer CM; Sominskaya I; Skrastina D; Pumpens P; El Wahed AA; Beutling U; Frank R; Fritz HJ; Hunsmann G; Gerlich WH; Glebe D
J Hepatol; 2011 Jul; 55(1):29-37. PubMed ID: 21145866
[TBL] [Abstract][Full Text] [Related]
7. Properties of modified hepatitis B virus surface antigen particles carrying preS epitopes.
Prange R; Werr M; Birkner M; Hilfrich R; Streeck RE
J Gen Virol; 1995 Sep; 76 ( Pt 9)():2131-40. PubMed ID: 7561750
[TBL] [Abstract][Full Text] [Related]
8. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.
Chen X; Li M; Le X; Ma W; Zhou B
Vaccine; 2004 Jan; 22(3-4):439-46. PubMed ID: 14670326
[TBL] [Abstract][Full Text] [Related]
9. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus.
Yang HJ; Chen M; Cheng T; He SZ; Li SW; Guan BQ; Zhu ZH; Gu Y; Zhang J; Xia NS
World J Gastroenterol; 2005 Jan; 11(4):492-7. PubMed ID: 15641132
[TBL] [Abstract][Full Text] [Related]
10. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.
Whitacre DC; Peters CJ; Sureau C; Nio K; Li F; Su L; Jones JE; Isogawa M; Sallberg M; Frelin L; Peterson DL; Milich DR
Hum Vaccin Immunother; 2020; 16(2):251-268. PubMed ID: 31809638
[TBL] [Abstract][Full Text] [Related]
11. Characterization of hepatitis B virus surface antigen particles expressed in stably transformed mammalian cell lines containing the large, middle and small surface protein.
Battagliotti JM; Fontana D; Etcheverrigaray M; Kratje R; Prieto C
Antiviral Res; 2020 Nov; 183():104936. PubMed ID: 32979402
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective.
Neurath AR; Seto B; Strick N
Vaccine; 1989 Jun; 7(3):234-6. PubMed ID: 2476893
[TBL] [Abstract][Full Text] [Related]
13. Humoral Immune Response in Mice Elicited by Combined Yeast-Derived Hepatitis B Virus Core, Surface, and Mosaic Surface Antigens.
Granovski V; Yokosawa J; Rodrigues-Granovski V; Castro CC; Urbina AC; Granovski N
Intervirology; 2017; 60(3):90-101. PubMed ID: 28957812
[TBL] [Abstract][Full Text] [Related]
14. Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins.
Hu WG; Wei J; Xia HC; Yang XX; Li F; Li GD; Wang Y; Zhang ZC
World J Gastroenterol; 2005 Apr; 11(14):2088-94. PubMed ID: 15810073
[TBL] [Abstract][Full Text] [Related]
15. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
Wei S; Lei Y; Yang J; Wang X; Shu F; Wei X; Lin F; Li B; Cui Y; Zhang H; Wei S
Vaccine; 2018 Apr; 36(17):2273-2281. PubMed ID: 29576303
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus surface antigen (HBsAg) as carrier for synthetic peptides having an attached hydrophobic tail.
Neurath AR; Strick N; Girard M
Mol Immunol; 1989 Jan; 26(1):53-62. PubMed ID: 2467197
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus.
Czarnota A; Tyborowska J; Peszyńska-Sularz G; Gromadzka B; Bieńkowska-Szewczyk K; Grzyb K
Microb Cell Fact; 2016 Apr; 15():62. PubMed ID: 27075377
[TBL] [Abstract][Full Text] [Related]
18. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
[TBL] [Abstract][Full Text] [Related]
19. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice.
Yue Q; Hu X; Yin W; Xu X; Wei S; Lei Y; Lü X; Yang J; Su M; Xu Z; Hao X
J Virol Methods; 2007 Apr; 141(1):41-8. PubMed ID: 17197041
[TBL] [Abstract][Full Text] [Related]
20. A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies.
Malik IR; Chen A; Brass A; Ahlén G; Rahman M; Sällberg M; Qureshi JA; Frelin L
Scand J Infect Dis; 2012 Jan; 44(1):55-9. PubMed ID: 21933033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
